Evidence map›Paper›PMID 24924953›Full record

ArticleInternational journal of hematology2014

Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.

Bor-Sheng Ko, Cheng-Shyong Chang, Ming-Chih Chang, Tsai Yun Chen, Tzeon-Jye Chiou, Chang-Fang Chiu, Wen-Li Huang, Woei-Yau Kao, Yii-Jenq Lan, Shen-Fung Lin and 6 more

Abstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Current treatment algorithm for the management of lower-risk MDS.Hematology. American Society of Hematology. Education Program · 2017
    Review
  2. Status of Superoxide Dismutase in Transfusion Dependent Thalassaemia.North American journal of medical sciences · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bor-Sheng KoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Cheng-Shyong Chang
Ming-Chih Chang
Tsai Yun Chen
Tzeon-Jye Chiou
Chang-Fang Chiu
Wen-Li Huang
Woei-Yau Kao
Yii-Jenq Lan
Shen-Fung Lin
Tran-Der Tan
Jih-Luh Tang
Cheng-Hwai Tzeng
Po-Nan Wang
Su-Pen Yet
Hwei-Fang Tien

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron overload is common in myelodysplastic syndrome (MDS) patients, and an accumulation of evidence shows that iron chelation may have benefits in these patients. However, discussion and consensus about iron chelation therapy (ICT) for MDS patients is lacking in Taiwan and other Southeast Asian countries. An Expert Panel in Taiwan was organized in 2011 to develop iron overload guidelines and provide a uniform reference for physicians treating MDS patients with iron overload, with specific regard to when to initiate ICT, in which patients, and the clinical and scientific rationale behind its use.

Indexed as

Chelation TherapyHematopoiesisHumansIron Chelating AgentsIron OverloadMyelodysplastic SyndromesPractice Guidelines as TopicSurvival AnalysisTaiwanIron Chelating Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.